DOXORRUBICINA MECANISMO DE ACCION PDF
complicado mecanismo de acción antitumoral como con sus efectos .. inhibidores de la topoisomerasa II (doxorrubicina, etopósido. mecanismo de acción de antineoplasicos. AV Doxorrubicina (antraciclina). – Lesión del ADN. –Inhibición topoisomerasa II. –Vía intravenosa. Abraxane (nombre genérico: paclitaxel unido a albúmina (nab-paclitaxel)) · Adriamicina (nombre genérico: doxorrubicina) · Carboplatino.
|Published (Last):||25 September 2013|
|PDF File Size:||2.21 Mb|
|ePub File Size:||6.19 Mb|
|Price:||Free* [*Free Regsitration Required]|
Patients who have already received the maximum cumulative dosage of anthracyclines should not receive intravesicle epirubicin. The decreased incidence of clinically significant cardiac toxicity associated with epirubicin as compared to doxorubicin is due to the more rapid clearance of epirubicin and possibly, glucuronidation of epirubicin.
The overall survival following both regimens was not superior to other treatments. Epirubicin is a severe vesicant. Patients with prior treatment with radiation therapy or anthracyclines may have decreased ability to tolerate trastuzumab therapy.
In addition, epirubicin has a lower incidence of cardiotoxicity; the maximum cumulative dose is almost medanismo that of doxorubicin.
As this can be a progressive injury, appropriate long-term follow-up is required. It is thought that myocardial damage and ventricular dysfunction progress mecznismo lead to late-onset cardiac dysfunction following treatment with anthracyclines. Signs and symptoms of anaphylactic reactions include skin rash unspecifiedpruritus, fever, chills and anaphylactic shock.
Cyclosporine, valspodar PSCtrifluoperazine, tamoxifen, toremifene, and verapamil doxodrubicina block the multidrug resistance MDR glycoprotein, which is a mechanism of resistance to naturally occurring non-synthetic chemotherapy agents. The ECF regimen resulted in an increased response and survival benefit for patients with previously untreated gastric cancer or head and neck cancer.
There was a problem providing the content you requested
It is characterized by facial flushing and acxion erythematous streaking along the vein. Epirubicin is an anthracycline chemotherapy agent and is the 4′-epimer of doxorubicin and a semi-synthetic derivative of daunorubicin. It does not appear dexrazoxane affects the clinical efficacy or non-cardiac toxicity of epirubicin. Several compounds including cyclosporine, cyclosporine analogs and verapamil may block this protein and reverse resistance.
Medicamentos de quimioterapia
Conjunctivitis and keratitis have been reported with epirubicin chemotherapy. Intramuscular administration and subcutaneous administration of epirubicin are contraindicated due to severe skin and tissue necrosis. Patients, especially those with dental disease, should be instructed in proper oral hygiene, including caution in use of regular toothbrushes, dental floss, and toothpicks.
Patients who have received adjuvant epirubicin in clinical trials show a cumulative risk of secondary acute myelogenous leukemia of about 0. Weekly paclitaxel doxorrubicinw epirubicin as second-line therapy of metastatic breast cancer: Topical cooling does not reduce anthracycline skin concentrations but decreases cellular uptake of anthracyclines thereby decreasing the cytotoxic effect.
Dosage adjustments accioh required for patients with hepatic or renal dysfunction. The esophagus can be especially sensitive. Regrowth of hair usually resumes 3 weeks after therapy has been discontinued. It is prudent to closely monitor patients for loss of mecanismi efficacy of digoxin while receiving antineoplastic therapy. Symptoms of extravasation are usually immediate although extravasations into chest wall tissue are less acutely symptomatic.
Intramuscular injections should not be administered to patients with platelet counts 60 years.
EPIRUBICINA EN VADEMECUM
The coadministration of paclitaxel or docetaxel did not affect the pharmacokinetics of epirubicin when epirubicin was given mecwnismo following the taxane. Dexrazoxane does appear to limit epirubicin-induced cardiotoxicity.
Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: The FDA approved epirubicin for the adjuvant treatment of node-positive breast cancer in September Epirubicin is considered cell cycle non-specific. In one case, a woman was 28 weeks pregnant at her diagnosis of breast cancer and was treated with cyclophosphamide and epirubicin every 3 weeks for 3 cycles.
Epirubicin should not be administered during pregnancy because of the possibility of teratogenic effects. The resulting hyperuricemia could aggravate gout or urate nephrolithiasis. Nail discoloration, photosensitivity, and skin discoloration have been reported.